- Home
- QURE vs TWST Comparison
QURE vs TWST Comparison
Compare QURE & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QURE | TWST |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2007 | 2018 |
Fundamental Metrics
Financial Performance| Metric | QURE | TWST |
|---|---|---|
| Price | $24.81 | $33.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $58.55 | $44.88 |
| AVG Volume (30 Days) | ★ 3.0M | 1.2M |
| Earning Date | 11-10-2025 | 02-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $15,751,000.00 | ★ $376,572,000.00 |
| Revenue This Year | N/A | $15.19 |
| Revenue Next Year | $153.45 | $15.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $7.76 | $23.30 |
| 52 Week High | $71.50 | $55.33 |
Technical Indicators
Market Signals| Indicator | QURE | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 45.82 | 56.07 |
| Support Level | $19.29 | $30.21 |
| Resistance Level | $25.69 | $35.39 |
| Average True Range (ATR) | 1.56 | 1.75 |
| MACD | 1.19 | 0.16 |
| Stochastic Oscillator | 88.24 | 56.95 |
Price Performance
Historical ComparisonAbout QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About TWST Twist Bioscience Corporation
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.